Lobna Ibrahim

4.5k total citations · 2 hit papers
21 papers, 3.5k citations indexed

About

Lobna Ibrahim is a scholar working on Pharmacology, Biological Psychiatry and Psychiatry and Mental health. According to data from OpenAlex, Lobna Ibrahim has authored 21 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 11 papers in Biological Psychiatry and 9 papers in Psychiatry and Mental health. Recurrent topics in Lobna Ibrahim's work include Treatment of Major Depression (14 papers), Tryptophan and brain disorders (11 papers) and Bipolar Disorder and Treatment (9 papers). Lobna Ibrahim is often cited by papers focused on Treatment of Major Depression (14 papers), Tryptophan and brain disorders (11 papers) and Bipolar Disorder and Treatment (9 papers). Lobna Ibrahim collaborates with scholars based in United States, Brazil and Czechia. Lobna Ibrahim's co-authors include Carlos A. Zarate, Nancy Diazgranados, David A. Luckenbaugh, Nancy E. Brutsché, Rodrigo Machado‐Vieira, Ioline D. Henter, Giacomo Salvadore, Husseini K. Manji, Jose Franco‐Chaves and Craig A. Marquardt and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and The Journal of Clinical Psychiatry.

In The Last Decade

Lobna Ibrahim

19 papers receiving 3.4k citations

Hit Papers

A Randomized Add-on Trial of an N-methyl-D-aspartate Anta... 2010 2026 2015 2020 2010 2012 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
    2010 734 citations Nancy Diazgranados, Lobna Ibrahim et al. Archives of General Psychiatry profile →
  2. Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
    2012 607 citations Carlos A. Zarate, Nancy E. Brutsché et al. Biological Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lobna Ibrahim United States 19 2.6k 2.3k 1.2k 824 561 21 3.5k
Paul J. Carlson United States 17 2.2k 0.8× 1.9k 0.8× 1.4k 1.1× 699 0.8× 717 1.3× 24 3.7k
Giacomo Salvadore United States 25 1.7k 0.7× 1.6k 0.7× 906 0.7× 854 1.0× 744 1.3× 51 3.4k
Andrew M. Perez United States 10 2.8k 1.1× 2.2k 1.0× 861 0.7× 615 0.7× 659 1.2× 15 3.4k
Angela Cappiello United States 12 2.3k 0.9× 1.9k 0.8× 1.7k 1.4× 606 0.7× 612 1.1× 14 3.8k
Raffaella Zanardi Italy 38 1.5k 0.6× 909 0.4× 1.3k 1.1× 1.7k 2.1× 639 1.1× 134 4.3k
Polymnia Georgiou United States 24 1.7k 0.6× 1.4k 0.6× 1.5k 1.2× 204 0.2× 423 0.8× 45 3.4k
Maggie Fedgchin United States 13 1.7k 0.7× 1.3k 0.6× 537 0.4× 396 0.5× 261 0.5× 24 2.1k
Alan L. Pehrson United States 23 1.1k 0.4× 565 0.3× 904 0.7× 435 0.5× 558 1.0× 63 2.4k
Masaaki Iwata Japan 19 1.5k 0.6× 2.4k 1.1× 1.8k 1.4× 387 0.5× 590 1.1× 63 4.9k
Arne Mørk Denmark 33 1.1k 0.4× 622 0.3× 1.9k 1.6× 824 1.0× 551 1.0× 93 4.0k

Countries citing papers authored by Lobna Ibrahim

Since Specialization
Citations

This map shows the geographic impact of Lobna Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lobna Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lobna Ibrahim more than expected).

Fields of papers citing papers by Lobna Ibrahim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lobna Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lobna Ibrahim. The network helps show where Lobna Ibrahim may publish in the future.

Co-authorship network of co-authors of Lobna Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Lobna Ibrahim. A scholar is included among the top collaborators of Lobna Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lobna Ibrahim. Lobna Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ibrahim, Lobna, et al.. (2025). Unveiling the Therapeutic Potential of Targeting RRM2 in Hepatocellular Carcinoma: An Integrated In Silico and In Vitro Study. Functional & Integrative Genomics. 25(1). 123–123.
2.
Salam, Mustafa Abdul, Lobna Ibrahim, & Diaa Salama AbdElminaam. (2021). Earthquake Prediction using Hybrid Machine Learning Techniques. International Journal of Advanced Computer Science and Applications. 12(5). 28 indexed citations
3.
Carlson, Paul J., Nancy Diazgranados, Allison C. Nugent, et al.. (2013). Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. Biological Psychiatry. 73(12). 1213–1221. 138 indexed citations
4.
Nugent, Allison C., Nancy Diazgranados, Paul J. Carlson, et al.. (2013). Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disorders. 16(2). 119–128. 66 indexed citations
5.
Zarate, Carlos A., Daniel C. Mathews, Lobna Ibrahim, et al.. (2012). A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression. Biological Psychiatry. 74(4). 257–264. 203 indexed citations
6.
Zarate, Carlos A., Nancy E. Brutsché, Lobna Ibrahim, et al.. (2012). Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial. Biological Psychiatry. 71(11). 939–946. 607 indexed citations breakdown →
7.
Ibrahim, Lobna, Nancy Diazgranados, Jose Franco‐Chaves, et al.. (2012). Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. Neuropsychopharmacology. 37(6). 1526–1533. 242 indexed citations
8.
Ibrahim, Lobna, Nancy Diazgranados, Nancy E. Brutsché, et al.. (2012). A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder. Journal of Clinical Psychopharmacology. 32(4). 551–557. 175 indexed citations
9.
Luckenbaugh, David A., Lobna Ibrahim, Nancy E. Brutsché, et al.. (2012). Family history of alcohol dependence and antidepressant response to an N‐methyl‐D‐aspartate antagonist in bipolar depression. Bipolar Disorders. 14(8). 880–887. 54 indexed citations
10.
Zhao, Xiaochen, Swarajya Lakshmi Vattem Venkata, Ruin Moaddel, et al.. (2012). Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment‐resistant bipolar depression. British Journal of Clinical Pharmacology. 74(2). 304–314. 113 indexed citations
11.
Machado‐Vieira, Rodrigo, Lobna Ibrahim, Ioline D. Henter, & Carlos A. Zarate. (2011). Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacology Biochemistry and Behavior. 100(4). 678–687. 73 indexed citations
12.
Ibrahim, Lobna, Nancy Diazgranados, David A. Luckenbaugh, et al.. (2011). Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35(4). 1155–1159. 147 indexed citations
13.
Ibrahim, Lobna, W. Raymond Duncan, David A. Luckenbaugh, et al.. (2011). Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study. Brain Research Bulletin. 86(1-2). 129–133. 37 indexed citations
14.
Salvadore, Giacomo, Jan Willem van der Veen, Yan Zhang, et al.. (2011). An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. The International Journal of Neuropsychopharmacology. 15(8). 1063–1072. 81 indexed citations
15.
Machado‐Vieira, Rodrigo, Giacomo Salvadore, Nancy Diazgranados, et al.. (2010). New Therapeutic Targets for Mood Disorders. The Scientific World JOURNAL. 10. 713–726. 50 indexed citations
16.
Machado‐Vieira, Rodrigo, Lobna Ibrahim, & Carlos A. Zarate. (2010). Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene‐Environment Interactions. CNS Neuroscience & Therapeutics. 17(6). 699–704. 93 indexed citations
17.
Diazgranados, Nancy, Lobna Ibrahim, Nancy E. Brutsché, et al.. (2010). A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Archives of General Psychiatry. 67(8). 793–793. 734 indexed citations breakdown →
18.
Diazgranados, Nancy, Lobna Ibrahim, Nancy E. Brutsché, et al.. (2010). Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry. 71(12). 1605–1611. 454 indexed citations
19.
Zarate, Carlos A., Rodrigo Machado‐Vieira, Ioline D. Henter, et al.. (2010). Glutamatergic Modulators: The Future of Treating Mood Disorders?. Harvard Review of Psychiatry. 18(5). 293–303. 164 indexed citations
20.
Machado‐Vieira, Rodrigo, Giacomo Salvadore, Lobna Ibrahim, Nancy Diazgranados, & Carlos A. Zarate. (2009). Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders. Current Pharmaceutical Design. 15(14). 1595–1611. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul J. Carlson Breakdown of academic impact, for papers by Giacomo Salvadore Breakdown of academic impact, for papers by Andrew M. Perez Breakdown of academic impact, for papers by Angela Cappiello Breakdown of academic impact, for papers by Raffaella Zanardi Breakdown of academic impact, for papers by Polymnia Georgiou Breakdown of academic impact, for papers by Maggie Fedgchin Breakdown of academic impact, for papers by Alan L. Pehrson Breakdown of academic impact, for papers by Masaaki Iwata Breakdown of academic impact, for papers by Arne Mørk
Rankless by CCL
2026